Ken Mariash appointed as Sinaptica’s chief executive officer

Sinaptica Therapeutics has announced the appointment of Ken Mariash Jr as chief executive officer, bringing with him more than 25 years of life sciences leadership experience in strategy, corporate development and marketing across both medtech and biotech.
Mariash’s experience spans roles at CSL Behring, Baxter BioScience and Boston Scientific, a decade of this experience being in the neuromodulation sphere.
Prior to joining Sinaptica, Mariash worked as founder and managing partner of Rubicon Strategy Partners, vice president of marketing at EBT Medical, director of strategy and new markets for the neuromodulation division of Boston Scientific. Before this he held roles in strategy and business development at Baxter BioScience (now known as Takeda), as well as working at CSL Behring and Charles River Associates in his early career.
Mariash commented: “I’m excited to take on this leadership role at Sinaptica at a time when our mechanistic understanding of AD pathology is evolving – the world is starting to appreciate new targets and new approaches like neuromodulation, which have the potential to significantly bend the curve of disease progression. After decades of drug failures, we applaud the recent progress of those targeting amyloid; however there remains a massive unmet need for safe, effective – and perhaps complementary – approaches.”
Rich Macary, president of Sinaptica Therapeutics, added: “As Sinaptica prepares for a pivotal clinical trial of our closed-loop neuromodulation therapy, Ken is the ideal choice to lead the company through this important stage. He brings a rare combination of drug, device, neuromodulation, and AD experience together with a broad skill set ranging from product development to capital equipment commercialisation. We have incredible confidence in Ken’s ability to take Sinaptica through the development stage toward commercialisation, and that his leadership will guide the company to realise the full potential of this transformative therapy to impact the lives of patients with Alzheimer’s disease.”